---
title: 'An advanced NSCLC patient with <em>ALK-RNF144A</em> and <em>HIP1-ALK</em>
  fusions treated with <em>ALK</em>-TKI combination therapy: a case report'
date: '2024-01-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38205210/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240111170708&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: We have reported an advanced NSCLC patient with a complex
  nonreciprocal/reciprocal ALK translocation containing a novel ALK-RNF144A fusion,
  concurrent with a RB1 loss-of-function mutation, who subsequently experienced pathological
  squamous cell carcinoma transformation. The combined treatment with ALK-TKI, chemotherapy,
  and anti-angiogenesis demonstrates clinical efficacy and may provide optional therapeutic
  strategies for this ...'
disable_comments: true
---
CONCLUSIONS: We have reported an advanced NSCLC patient with a complex nonreciprocal/reciprocal ALK translocation containing a novel ALK-RNF144A fusion, concurrent with a RB1 loss-of-function mutation, who subsequently experienced pathological squamous cell carcinoma transformation. The combined treatment with ALK-TKI, chemotherapy, and anti-angiogenesis demonstrates clinical efficacy and may provide optional therapeutic strategies for this ...